Diabetes and Endocrinology Trials

Important Trials in Diabetes and Endocrinology 2023
 4 Topics
The ONWARDS3 Clinical Trial
Is Testosterone Therapy Safe for the Heart? Insights from the TRAVERSE Study
Retatrutide Clinical Trial
Orforglipron vs. Type 2 Diabetes: A Breakthrough in Oral Treatment?
Important Trials in Diabetes and Endocrinology 2021
 14 Topics
Bone Mineral Density and Turnover After Sleeve Gastrectomy and Gastric Bypass.
SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
STEP 1 : Semaglutide Treatment Effect in People with Obesity
SOLOIST-WHF: Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure.
SCORED : Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
MOBILE : Continuous Glucose MOnitoring in T2D Basal InsuLin UsErs.
Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes
FIDELIO-DKD: Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease
EMPEROR-Preserved: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction.
COMPASS: Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia
AMPLITUDE-O: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation.
ACTIVE : Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Reproductive Endocrinology
 8 Topics
WHI E + P
AMIGOS : Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility
HERS Study
KEEPS Study : Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial
PCOS (LETROZOLE STUDY)
FET
ELITE – The Early versus Late Intervention Trial with Estradiol
PCOS
Diabetes Mellitus
 24 Topics
ADVANCE : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
ACCORD : Effects of intensive glucose lowering in type 2 diabetes
CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
D2d TRIAL: Vitamin D Supplementation and Prevention of Type 2 Diabetes.
DCCT : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
DPP: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The Diabetes Prevention Program
HAPO: Hyperglycemia and Adverse Pregnancy Outcomes. The HAPO Study Cooperative Research Group
LEADER : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Look AHEAD – Look Action for HEAlth in Diabetes.
NICE-SUGAR : Intensive versus conventional glucose control in critically ill patients
CREDENCE
DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
DECLARE-TIMI 58
iDCL: The international Diabetes Closed Loop Trial: The Clinical Acceptance of the Artificial Pancreas
Look AHEAD: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Look Action for HEAlth in Diabetes.
RENAAL: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
UKPDS 33
U500-R (“HOOD study”)
PROactive
1 of 2
Calcium and Bone Metabolism
 7 Topics
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
FIT : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
PTH(1-34) : Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
FRAME : Romosozumab Treatment in Postmenopausal Women with Osteoporosis
FREEDOM : Denosumab for prevention of fractures in postmenopausal women with osteoporosis
HORIZON : Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Zoledronic Acid Recurrent Fracture Trial
Pituitary Disorders
 2 Topics
PASIREOTIDE B2305 STUDY GROUP : A 12-month phase 3 study of pasireotide in Cushing’s disease
COPEPTIN – A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus
Lipidology and Obesity
 13 Topics
RECORD: Rosiglitazone Evaluated for Cardiovascular Outcomes in oRal agent combination therapy for type 2 Diabetes mellitus
4S : The Scandinavian Simvastatin Survival Study
JUPITER – Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
IMPROVE-IT : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
HPS3/TIMI55 : Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
HOPE-3 Trial : Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
ASCEND : Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
CONQUER
CAMELLIA-TIMI 61 : Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
COR1
STAMPEDE : Bariatric surgery versus intensive medical therapy in obese patients with diabetes
ORIGIN N-3 Fatty Acid
ODYSSEY OUTCOMES : Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Hypertension and Adrenal Disorders
 2 Topics
SPRINT
SPYRAL HTN-ON MED
Thyroid Diseases
 7 Topics
SCH – Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy.
DECISION STUDY
OPTIC – Treatment of Graves’ Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in a Clinical Study
RAI
TABLET – Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Thyroid AntiBodies and LEvoThyroxine study
WDTC
ZETA Study
Previous Topic
Next Topic

CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Diabetes and Endocrinology Trials Diabetes Mellitus CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

CANVAS : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

• FDA approved for reduction of cardiac mortality in adults with T2DM and established CVD.

• Canagliflozin is a suggested add-on therapy to metformin for patients with T2DM patients with established CVD (AACE 2019).

Infographic

Reference

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657.

Previous Topic
Back to Lesson
Next Topic
>